Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.0065 USD
Change Today -0.0002 / -3.70%
Volume 1.9M
BHRT On Other Exchanges
Symbol
Exchange
OTC US
As of 2:12 PM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

bioheart inc (BHRT) Snapshot

Open
$0.0070
Previous Close
$0.0068
Day High
$0.0079
Day Low
$0.0062
52 Week High
07/24/14 - $0.04
52 Week Low
04/14/15 - $0.0045
Market Cap
4.2M
Average Volume 10 Days
7.0M
EPS TTM
$-0.0070
Shares Outstanding
647.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOHEART INC (BHRT)

Related News

No related news articles were found.

bioheart inc (BHRT) Related Businessweek News

No Related Businessweek News Found

bioheart inc (BHRT) Details

Bioheart, Inc., a development stage biotechnology company, focuses on the discovery, development, and commercialization of autologous cell therapies for the treatment of chronic and acute heart damage, and degenerative diseases. Its lead product candidate is MyoCell, a clinical muscle-derived cell therapy that has completed Phase II-a study and populates regions of scar tissue within a patient’s heart with new living cells for improving cardiac function in chronic heart failure patients. The company also develops MyoCell SDF-1, an autologous cell therapy treatment for severe chronic damage to the heart and cells modified to express angiogenic factors; AdipoCell, an adipose cell therapy treatment for the management of progressive heart failure; and MyoCath, a disposable endoventricular catheter used for the delivery of biologic solutions to the myocardium. In addition, its preclinical stage product candidates include MyoCath II, which provides multidirectional cell injection, as well as is used for the delivery of biologic solutions to the myocardium. Bioheart, Inc. was founded in 1999 and is headquartered in Sunrise, Florida.

3 Employees
Last Reported Date: 03/16/15
Founded in 1999

bioheart inc (BHRT) Top Compensated Officers

Chief Executive Officer, President, Chief Fin...
Total Annual Compensation: $766.7K
Chief Scientific Officer, Director and Member...
Total Annual Compensation: $284.2K
Compensation as of Fiscal Year 2013.

bioheart inc (BHRT) Key Developments

Bioheart, Inc. Reports Earnings Results for the Year 2014

Bioheart, Inc. reported earnings results for the year 2014. For the year, the company reported 2,040% increase in year over year revenues to $2.1 million in 2014 from $0.1 million in 2013. Net loss was $2.25 million against $3.14 million a year ago. Cash used in operating activities was $1.1 million against $1.9 million a year ago.

Bioheart, Inc., Special/Extraordinary Shareholders Meeting, Feb 02, 2015

Bioheart, Inc., Special/Extraordinary Shareholders Meeting, Feb 02, 2015., at 09:00 US Eastern Standard Time. Location: 13794 NW 4 Street. Agenda: To elect seven directors of the company; to ratify the appointment of Fiondella, Milone, and LaSaracina LLP, as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2015; to approve the 2013 Omnibus Equity Compensation Plan; to consider and, if deemed advisable, approve an advisory vote on executive compensation; to consider an advisory vote determining the frequency of future executive compensation advisory votes; and to transact such other business as may properly come before the Meeting.

Bioheart, Inc. Announces Positive 12 Month Preliminary Data From Phase I Angel Trial

Bioheart, Inc. released the preliminary 12 month data from its phase I ANGEL Trial. Fully funded by Bioheart, the trial is being conducted in Mexico at the Hospital Angeles in conjunction with the Regenerative Medicine Institute (RMI). At the 12 month time point, patients are demonstrating a statistically significant average improvement in ejection fraction (EF) by echocardiogram. At the 3 month time point, 100% of the patients demonstrated either improvement or stayed the same. After 3 months, patients showed an average absolute improvement of 3 percentage points in EF. The patients continued to improve from 3 months to 6 months with a statistically significant average absolute improvement of 10 percentage points (p=0.01) and at the 12 month follow up patients showed this same level of improvement (p=0.01). This phase I study will provide necessary safety and preliminary efficacy of adipose derived stem cells (AdipoCell(TM)) in patients with congestive heart failure. Endpoints include safety, exercise capacity, quality of life, and ejection fraction at 3 months, 6 months and 12 months.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BHRT:US $0.01 USD -0.0002

BHRT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Athersys Inc $1.24 USD -0.05
Cesca Therapeutics Inc $0.91 USD +0.002
International Stem Cell Corp $0.07 USD -0.0015
Nuo Therapeutics Inc $0.19 USD -0.0119
StemCells Inc $0.61 USD +0.0002
View Industry Companies
 

Industry Analysis

BHRT

Industry Average

Valuation BHRT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.8x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOHEART INC, please visit www.bioheartinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.